TRANSIL MSA Binding Kit

Sovicell Verified independent store

→

Determination of Drug–Mouse Albumin Binding Constants for Interpretation of Mouse Pharmacokinetic Studies The TRANSIL MSA Binding Kit enables mechanistic characterization of drug b inding to mouse serum albumin to support interpretation of pharmacokinetic studies in preclinical models. It determines the binding affinity (K D ) of test compounds to mouse serum albumin (MSA) under well-defined experimental conditions. These affinity constants enable prediction of plasma protein binding and free drug fraction in drug discovery and development. Why Albumin Binding Matters Most drug molecules are reversibly bound to proteins in plasma. Only the unbound fraction (fu) can cross biological membranes, interact with pharmacological targets, or undergo metabolic elimination. Plasma protein binding therefore strongly influences drug exposure, pharmacokinetics, and pharmacological activity. Serum albumin is the most abundant plasma protein in both humans and many preclinical species and represents the principal binding partner for many drugs. Because albumin binding can substantially reduce the circulating free drug concentration, accurate characterization of drug–albumin interactions is an important component of ADME profiling and lead optimization. Characterizing albumin binding in preclinical species such as mouse is therefore important for interpreting pharmacokinetic data obtained in animal studies and for translating exposure between species. Albumin binding influences many key parameters in ADME and DMPK, including: prediction of the unbound drug fraction in plasma interpretation of potency in serum-containing assays estimation of clearance, half-life, and volume of distribution assessment of potential drug–drug interactions modeling of drug exposure under varying physiological conditions The measured KD can be used to estimate plasma protein binding across different albumin concentrations, reflecting physiological variability or disease-associated changes in protein levels. Albumin Binding in Preclinical Species Determination of plasma protein binding in preclinical species is an important component of pharmacokinetic studies during drug discovery. Differences in albumin binding between species can influence the relationship between dose, plasma exposure, and pharmacological response. Measuring the binding affinity of compounds to mouse serum albumin therefore supports the interpretation of preclinical PK studies and cross-species comparisons of drug exposure. Mouse models are widely used in preclinical pharmacology and disease research, including genetically modified models and tumor xenograft studies. Characterizing albumin binding in mouse plasma therefore helps interpret drug exposure and pharmacological effects in these experimental systems. Limitations of Conventional Plasma Protein Binding Assays Conventional approaches for measuring plasma protein binding, such as equilibrium dialysis, ultrafiltration, and ultracentrifugation, directly determine the free fraction of a compound in plasma. While widely used, these methods can be time-consuming and experimentally demanding, often requiring long equilibration times and careful control of experimental conditions. In addition, adsorption to membranes or plastic surfaces, compound instability, and analytical sensitivity limitations can complicate the accurate measurement of highly bound compounds. These challenges make it difficult to apply traditional methods efficiently in high-throughput drug discovery workflows. The TRANSIL Approach Unlike plasma-based methods, the TRANSIL approach determines intrinsic drug–albumin binding affinity under controlled conditions, allowing plasma protein binding to be predicted across different physiological albumin concentrations. The TRANSIL MSA Binding Kit determines albumin binding affinity by measuring the dissociation constant (KD) of the interaction between a test compound and mouse serum albumin. In the assay, compounds are incubated with increasing concentrations of albumin immobilized on high-surface-area beads under well- defined experimental conditions. The resulting binding data are used to calculate the affinity constant of the drug-albumin interaction, which provides a mechanistic description of protein binding. Because the KD describes the intrinsic drug–albumin interaction and is independent of protein concentration, it can be used to predict plasma protein binding and free drug fraction under physiological conditions and across different albumin concentrations. How the Assay Works The assay determines albumin binding affinity through the following experimental workflow: Test compound is added at constant concentration to 8 wells The compound is incubated with increasing concentrations of bead- immobilized albumin Beads are separated, leaving only free drug in solution Free drug concentration is quantified (e.g., by LC–MS/MS) Binding affinity (KD) is calculated from the slope of binding versus protein concentration Features and Benefits Membrane-free binding measurement Immobilization of albumin on beads eliminates the need for dialysis membranes, accelerating equilibration between compound and protein while avoiding artifacts caused by membrane adsorption or slow diffusion through dialysis membranes. Rapid equilibrium measurements Immobilized albumin on high-surface-area beads enables equilibrium binding measurements within 12 minutes or less rather than the hours required for dialysis-based methods. Mechanistic characterization of albumin binding Determines the drug–albumin dissociation constant (KD), providing a mechanistic description of the interaction and enabling prediction of plasma protein binding across different physiological protein concentrations. Robust performance for challenging compounds Affinity is derived from the relationship between binding and protein concentration, making the method largely insensitive to compound loss caused by nonspecific adsorption or limited recovery. Stable and controlled pH conditions The assay is performed in a well-defined buffered environment, preventing errors in free fraction (fu) estimation caused by pH shifts that can occur in dialysis experiments. Well-defined experimental conditions Binding is measured against purified albumin at controlled concentrations, reducing variability associated with plasma composition and improving reproducibility. High-throughput assay format The 96-well format allows analysis of up to 12 compounds per plate, supporting efficient profiling during lead optimization. Compatibility with standard analytical methods Free compound concentration can be quantified using LC–MS/MS, HPLC, or other commonly used analytical techniques, allowing integration into existing workflows. Integrated internal quality control The TRANSIL Quality Index (TQI) evaluates data reliability using multiple statistical and experimental metrics, providing an objective assessment of assay performance within each experiment. Method Validation and Cross-Species Applicability The TRANSIL technology has been extensively validated using human serum albumin (HSA), where albumin binding constants determined with the TRANSIL assay show strong agreement with plasma protein binding data obtained by equilibrium dialysis and reported in the literature. Because the assay measures the intrinsic binding affinity between a compound and albumin, the same experimental principle can be applied to albumin from other species. The TRANSIL MSA Binding Kit therefore enables mechanistic characterization of drug binding to mouse serum albumin (MSA) under the same well-defined experimental conditions used for the human assay. Measurement of albumin binding in preclinical species is frequently required to interpret pharmacokinetic studies in animal models and to support translation between preclinical and human exposure. Determining binding affinity to MSA therefore provides important information for ADME studies and pharmacokinetic modeling in mouse experiments. What are the main quality control measures applied in TRANSIL assays? The TRANSIL Quality Index (TQI) is based on independent measures derived from the data analysis. Overall fit of the data to the standard protein binding model Recovery: does the model derived compound concentration equal the true concentration? Data consistency: does membrane binding increase proportionally with the increasing TRANSIL bead content in each well? Data consistency: are the estimated reference concentrations in alignment with the compound concentration used? Missing data and outliers. How long does it take to run the assay? One assay plate can be used for 12 compounds. Thus, you’ll need to pipette 15 µl of test item to each of 8 wells and repeat this for all 12 compounds. This takes less than 10 minutes even with manual pipetting. After compound addition, the plate is ready for incubation. You can do this with an electronic 8 or 12 channel pipette by aspirating and dispensing a volume of 120 µl for 15 times. That takes just over a minute for each column or row. In total, that makes 8 to 15 minutes depending on your pipette. When using a pipetting robot with a 96 well head this time decreases to 2 minutes. After incubation, the plate needs to be spun in a plate centrifuge for 10 minutes. The supernatants are then ready for quantification by LC/MS/MS, UV, fluorescence or any other method of your choice. Thus, the total time the start and end of the experiment varies between 7 and 25 minutes depending upon your equipment. How many compounds can be analyzed with one plate? One assay plate can be used for 12 compounds. A special feature of the 96 well plates used for these kits is that each of the 12 columns can be separated from the plate. Thus, it is possible to use the plate for one compound at a time. Are TRANSIL assay kits supplied in low-binding plates? The TRANSIL assay kits utilize Micronic 96 well plates with ultra-low-binding tubes. Standard polypropylene tubes have 41x higher non-specific binding and low-binding tubes from other vendors have 2.6x higher non-specific binding. Show more